Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.

Paul M Barr,Carolyn Owen,Tadeusz Robak,Alessandra Tedeschi,Osnat Bairey,Jan A Burger,Peter Hillmen,Claire Dearden,Sebastian Grosicki,Helen McCarthy,Jian Yong Li,Fritz Offner,Carol Moreno,Mandy Jermain,Cathy Zhou,Emily Hsu,Anita Szoke,Thomas J Kipps,Paolo Ghia

Future oncology (London, England)（2022）

引用 0|浏览7

暂无评分

摘要

In people with CLL or SLL, more participants who were taking ibrutinib were alive without worsening of their disease after 7 years compared with participants who took chlorambucil. : NCT01722487 (ClinicalTrials.gov) : NCT01724346 (ClinicalTrials.gov).

查看译文

关键词

chronic lymphocytic leukemia,clinical trial,ibrutinib,lay summary,long-term efficacy,long-term safety,plain language summary,small lymphocytic lymphoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要